Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation

Dennis H. Lau, Anand Thiyagarajah, Stephan Willems, Thomas Rostock, Dominik Linz, Martin K. Stiles, David Kaye, Jonathan M. Kalman, Prashanthan Sanders

Research output: Contribution to journalReview articlepeer-review

13 Citations (Scopus)


Atrioventricular node ablation (AVNA) is generally reserved for patients whose atrial fibrillation (AF) is refractory all other therapeutic options, since the recipients will often become pacemaker dependent. In such patients, this approach may prove particularly useful, especially if a tachycardia-induced cardiomyopathy is suspected. Historically, an “ablate and pace” approach has involved AVNA and right ventricular pacing, with or without an atrial lead. There is also an evolving role for atrioventricular node ablation in patients with AF who require cardiac resynchronisation therapy for treatment of systolic heart failure. A mortality benefit over pharmacotherapy has been demonstrated in observational studies and this concept is being further investigated in multi-centre randomised control trials.

Original languageEnglish
Pages (from-to)934-940
Number of pages7
JournalHeart Lung and Circulation
Issue number9
Publication statusPublished or Issued - Sept 2017


  • Atrial fibrillation
  • Atrioventricular nodal ablation
  • Cardiac resynchronisation therapy
  • Device therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this